Protamine Neutralization of the Release of Tissue Factor Pathway Inhibitor Activity by Heparins

Summary

The present study was designed to investigate the action of protamine on the release of tissue factor pathway inhibitor (TFPI) activity by unfractionated (UF) and low molecular weight (LMW) heparin in healthy individuals. 5000 IU UF-heparin or 5000 IU LMW-heparin were given intravenously followed by saline, 5000 U protamine chloride or 5000 U protamine sulfate intravenously after the 10 min blood sample. Then serial blood samples for the measurement of TFPI activity and anti-factor Xa- activity were taken, in order to detect a possible relation between the remaining anti-factor X a activity after neutralization of LMW-heparin with protamine and TFPI activity and to establish whether or not a rebound phenomenon of plasmatic TFPI occurs.

There was no difference in the release and in the kinetics of TFPI by UF- and LMW-heparin with subsequent administration of saline. After administration of protamine TFPI activity decreased immediately and irreversibly to pretreatment values. There were no differences between protamine chloride and protamine sulfate on the effect of TFPI induced by UF- or LMW-heparin. No rebound phenomenon of TFPI activity occurred. In contrast anti-factor Xa- activity, as measured by the chromogenic S2222-assay, issued the known differences between UF- and LMW-heparin. The half-life of the aXa-effect of LMW-heparin was twice as long as of UF-heparin. Protamine antagonized UF-heparin completely and about 60% of the anti-factor Xa activity of LMW-heparin, using chromogenic S2222-method. No differences could be detected for protamine chloride and sulfate form of protamine

It is assumed that protamine displaces heparins from the binding sites of TFPI. There were no differences between UF- and LMW-heparin. The data indicate that the sustained antifactor Xa activity after antagonization of LMW-heparins as well as heparin rebound phenomena are not mediated by TFPI activity.

• References

• 1 Broze Jr GJ, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP. The lipoprotein-associated coagulation inhibitor that inhibits the factor VH-tissue factor complex also inhibits factor Xa: Insight into its possible mechanism of action. Blood 1988; 71: 335-343
• 2 Rapaport SI. Inhibition of factor VIIa/tissue factor-induced blood coagulation: With particular emphasis upon a factor Xa-dependent inhibition mechanism. Blood 1989; 73: 359-365
• 3 Wun TC, Kretzmer KK, Girard TJ, Miletich JP, Broze Jr GJ. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitztype inhibitory domains. J Biol Chem 1988; 263: 6001-6004
• 4 Girard TJ, Warren LA, Novotny WF, Likert KM, Brown SG, Miletich JP, Broze Jr GJ. Functional significance of the Kunitz-type inhibitor domains of lipoprotein-associated coagulation inhibitor. Nature 1989; 338: 518-520
• 5 Carson SD. Tissue factor (coagulation factor III) inhibition by apolipoprotein A-II. J Biol Chem 1987; 262: 718-721
• 6 Novotny WF, Girard TJ, Miletich JP, Broze Jr GJ. Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein-associated coagulation inhibitor. Blood 1988; 71: 2020-2025
• 7 Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988; 50: 803-813
• 8 Novotny WF, Brown SG, Miletich JP, Rader DJ, Broze Jr GJ. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood 1991; 78: 387-393
• 9 Lindahl AK, Abildgaard U, Staalesen R. The anticoagulant effect in heparinized blood and plasma resulting from interactions with extrinsic pathway inhibitor. Thromb Res 1991; 64: 155-168
• 10 Harenberg J, Schäfer M, Stehle G, Schmidt M, Dempfle CE, Heene DL. Release of the extrinsic pathway inhibitor, hepatic lipase and anti-factor Xa activity into post-heparin plasma. Thromb Haemostas 1991; 65: 915
• 11 Lindahl AK, Abildgaard U, Stokke G. Extrinsic pathway inhibitor after heparin injection: increased response in cancer patients. Thromb Res 1990; 59: 651-656
• 12 Lindahl AK, Jacobsen PB, Sandset PM, Abildgaard U. Tissue factor pathway inhibitor with high anticoagulant activity is increased in postheparin plasma and in plasma from cancer patients. Blood Coagul Fibrinolysis 1991; 2: 713-721
• 13 Norrheim L, Abildgaard U, Larsen ML, Lindahl AK. Involvement of the extrinsic pathway in the activities of low molecular weight heparins. Thromb Res (Suppl. 01) 1991; 14: 19-27
• 14 Sandset PM, Abildgaard U. Extrinsic pathway inhibitor – The key of feedback control of blood coagulation initiated by tissue thromboplastin. Haemostasis 1991; 21: 219-239
• 15 Harenberg J, Schäfer M, Stehle G, Dempfle CE, Heene DL. Release of the extrinsic pathway inhibitor into post-heparin plasma. Ann Haematol 1991; 56: A44
• 16 Lindahl AK, Abildgaard U, Larsen ML, Aamodt LM, Nordfang O, Beck TC. Extrinsic pathway inhibitor (EPI) and the post-heparin anticoagulant effect in tissue thromboplastin-induced coagulation. Thromb Res 1991; 64: 155-168
• 17 Haskel EJ, Torr SR, Day KC, Palmier MO, Wun TC, Sobel BE, Abendschein DR. Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein-associated coagulation inhibitor. Circulation 1991; 84: 821-827
• 18 Jorpes JE, Edman P, Thaning T. Neutralization of action of heparin by protamine. Lancet 1939; II: 975-976
• 19 Holmer E, Söderström G. Neutralization of unfractionated heparin and a low molecular weight (LMW) heparin fragment by protamine. Thromb Haemostas 1983; 50: 103 (Abstract)
• 20 Harenberg J, Gnasso A, de Vries JX, Zimmermann R, Augustin J. Inhibition of low-molecular-weight heparin by protamine chloride in vivo. Thromb Res 1985; 38: 11-20
• 21 Harenberg J, Wiirzner B, Zimmermann R, Schettler G. Bioavailability and antagonization of the low molecular weight heparin CY 216 in man. Thromb Res 1986; 44: 549-554
• 22 Diness V, Ostergaard PB. Neutralization of a low-molecular-weight heparin (LNH-1) and conventional heparin by protamine sulfate in rats. Thromb Haemostas 1986; 56: 318-324
• 23 Frick PG, Brögli H. The mechanism of heparin rebound after extracorporeal circulation for open cardial surgery. Surgery 1966; 59: 721-726
• 24 Gollub H. Heparin rebound in open heart surgery. Surg Gynecol Obstet 1967; 124: 337-346
• 25 Sandset PM, Larsen ML, Abildgaard U, Lindahl AK, Odegaard OR. Chromogenic substrate assay of extrinsic pathway inhibitor (EPI): levels in the normal population and relation to cholesterol. Blood Coagul Fibrinolysis 1991; 2: 425-433
• 26 Harenberg J, Giese CH, Knödler A, Zimmermann R. Comparative study on a new one-stage clotting assay for heparin and its low molecular weight derivatives. Haemostasis 1989; 19: 13-20
• 27 Alban S, Harenberg J. Neutralization of heparins and heparin-related oligosaccharides by protamine and polybrene. Pharm Pharmacol Let 1991; 1: 37-40